10 May 2016 : Original article
Obese Kidney Donors in the Laparoscopic Living Nephrectomy Era: How Safe?
Albertus MarcelinoABCDEFG, Chaidir Arif MochtarABCDE, Irfan WahyudiABCDE, Agus Rizal HamidABCDEDOI: 10.12659/AOT.896687
Ann Transplant 2016; 21:297-300
Abstract
BACKGROUND: Obesity is a major worldwide health problem, causing up to 3.4 million deaths per year. It is considered to be a relative contraindication for laparoscopic surgery. Laparoscopic living donor nephrectomy is the criterion standard procedure for kidney procurement in many transplant centers. However, the selection of the obese donors undergoing laparoscopic nephrectomies is still debatable. The objective of this study was to compare short-term results of obese donors and non-obese donors undergoing laparoscopic living donor nephrectomies.
MATERIAL AND METHODS: A retrospective analysis of 259 live donors between November 2011 and August 2015 was performed. Body mass index equal to or more than 30 kg/m2 was categorized as obese. Twenty subjects were categorized as obese donors. We randomly assigned for 30 non-obese donors to the control group. Intra-operative and post-operative data were compared between these 2 groups. A p-value ≤0.05 was considered a significant difference.
RESULTS: Donor characteristics were the same in the 2 groups. No significant differences were found in the first warm ischemic time, estimated blood loss, or postoperative pain. The operative time in the obese group was significantly longer than in the control group (270 vs. 245 min, p≤0.05). The hospital stay was also significantly longer in the obese group (4 vs. 3 days, p≤0.05).
CONCLUSIONS: At our hospital, obese donors had short-term results comparable to those of non-obese donors in laparoscopic living nephrectomy. While longer operative time and length of stay were found, there were no significant complications observed. Long-term outcomes should be evaluated to justify use of obese donors.
Keywords: Laparoscopy, Living Donors, Obesity, Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






